Q3 2025 Outlook Report | Evaluate
Explore the market catalysts driven by 23 drugs, devices, diagnostics, and deals anticipated in Q2 2025.| Evaluate
Explore the market catalysts driven by 23 drugs, devices, diagnostics, and deals anticipated in Q2 2025.| Evaluate
Explore Evaluate’s Q2 2025 biopharma report for the latest insights on M&A, IPOs, venture funding, and China’s rising influence. Essential reading for pharma, biotech, and pharma investors.| Evaluate
BIO International 2025 highlights, including trends in biotech investment, M&A activity, licensing, and the role of China in global biopharma. Download now for expert commentary, market statistics, and strategic guidance.| Evaluate
Explore advanced oncology forecasting strategies in our latest eBook—covering treatment pathways, biomarker segmentation, PD-1 therapies, and more. Download now| Evaluate
Discover key insights from Evaluate’s World Preview 2025 infographic, including GLP-1 growth, China’s biotech ascent, and looming patent expiries. Download now.| Evaluate
Master your pharma forecasting with epidemiology, patient-flow, and sales-based methodologies. Download the eBook for expert insights and best practices.| Evaluate
Make the most of the ASCO 2025 Annual Meeting with our expertly curated Weekend Planner, your essential tool for navigating the most commercially relevant presentations and data releases from oncology’s biggest event.| Evaluate
Pharma market growth forecasts and drug sales to 2030 reflect solid underlying demand. But much is changing across the biopharma landscape.| Evaluate
Drug sales to hit $1.75T by 2030, led by GLP-1s and China’s biotech rise amid global pharma shifts.| Evaluate
Key announcements and data from the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO), with accompanying analyses.| Evaluate
